Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ybrain Inc.
With
Severance Hospital
Gangnam Severance Hospital
Myongji Hospital
CHA University
National Health Insurance Service Ilsan Hospital
Ajou University
Hallym University Medical Center
Patients will be randomized to receive either real or sham-tDCS as well as anti-depressant drugs. tDCS will be applied over the left (anode) and right (cathode) dorsolateral prefrontal cortex (DLPFC). Patients will visit the hospital to get tDCS administrations 5 days a week for 2 weeks. They will be evaluated every 2 weeks.
Age
19–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has a diagnosis of a major depressive disorder as confirmed by the SCID-IV and MINI (without psychotic features)
Greater than 22 points of Montgomery-Asberg Depression Rating Scale
Aged 19 to 65.
Has provided informed consent
You may not be if
Has other mental disorders diagnosed by Axis-I, except major depressive disorder (However, subject who is diagnosed as both major depressive disorder as well as anxiety disorder can participate the study.)
History of suicidal attempt in the last 6 months
Diagnosed with bipolar or psychotic major depressive disorder
Diagnosed with other depressive disorders: dysthymic disorder, and depressive disorders that are not elsewhere classified.
Has hypersensitivity to sertraline ingredients
A score of 5 or greater for the question #10 in MADRS
Diagnosed with closed angle glaucoma or has a history of glaucoma.
History of participation in other clinical trials within 30days.
A major and/or unstable medical or neurologic illness
Currently taking substances that contain sertraline, mono amine oxidase inhibitor, or pimozide
Pregnant or has a positive pregnancy serum test.
Clareo Health | The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder
